CEO Carmine Stengone (Pipeline Therapeutics)
Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it
About three years after splitting from Versant Ventures’ discovery group, Pipeline Therapeutics has landed an $80 million Series C round to go “much broader” than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.